CAR-T–associated adverse events
| CAR-T-associated AEs Per ASTCT criteria CRS . | 100 million (N = 6) . | 300 million (N = 6) . | ||
|---|---|---|---|---|
| Grade 1/2 . | Grade 3 . | Grade 1/2 . | Grade 3 . | |
| 6 | 0 | 5 | 1 | |
| Median onset (min-max) | 2.5 d (0-4 d) | <24 h (0-1 d) | ||
| Median duration (min-max) | 5 d (2-7 d) | 3 d (1-9 d) | ||
| CAR-T-associated AEs Per ASTCT criteria CRS . | 100 million (N = 6) . | 300 million (N = 6) . | ||
|---|---|---|---|---|
| Grade 1/2 . | Grade 3 . | Grade 1/2 . | Grade 3 . | |
| 6 | 0 | 5 | 1 | |
| Median onset (min-max) | 2.5 d (0-4 d) | <24 h (0-1 d) | ||
| Median duration (min-max) | 5 d (2-7 d) | 3 d (1-9 d) | ||
| Neurotoxicity (ICANs) . | Grade 1/2 . | Grade 3 . | Grade 1/2 . | Grade 3 . |
|---|---|---|---|---|
| 1 | 0 | 0 | 1 | |
| Onset | 2 d | 6 d | ||
| Duration | 2 d | 14 d | ||
| Toxicity management | ||||
| Tocilizumab | 4 | 5 | ||
| Dexamethasone | 3 | 2 | ||
| Anakinra | 0 | 1 | ||
| Neurotoxicity (ICANs) . | Grade 1/2 . | Grade 3 . | Grade 1/2 . | Grade 3 . |
|---|---|---|---|---|
| 1 | 0 | 0 | 1 | |
| Onset | 2 d | 6 d | ||
| Duration | 2 d | 14 d | ||
| Toxicity management | ||||
| Tocilizumab | 4 | 5 | ||
| Dexamethasone | 3 | 2 | ||
| Anakinra | 0 | 1 | ||
ASTCT, American Society for Transplantation and Cellular Therapy; ICANS, immune effector cell-associated neurotoxicity.